United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 25

Name: Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 25 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderCerecor · 39

Strongest available pathEarth Science tech · +195.1%

Widest latest marginEarth Science tech · 9.8%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1AVTX · Nasdaq

Cerecor

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2011Wayne, Pennsylvania$1.02B market cap

View full Companies Radar profile

39Cautious

Snapshot price$18.95as of page date

Monthly-close return-99.7%five-year window

FY2025 revenue$0.00BAvalo Therapeutics, Inc.

Net margin-132642.4%FY2025

P/E snapshot-7.2xone ratio, not a verdict

Prism attention11.4%share across these five

Filing track recordRevenue, USD billions

-98.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -67.7%

52-week position66% through range

$8.65$24.27

News mentions658

Community mentions0partial coverage

U.S.-scope patents50

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal39/100
Management stability90/100
Market position11/100
Capital-event signal51/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 2 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2AVIR · NASDAQ

Atea

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2014Boston, Massachusetts$440.3M market cap

View full Companies Radar profile

38Cautious

Snapshot price$5.49as of page date

Monthly-close return-84.3%five-year window

FY2022 revenue$0.35BAtea Pharmaceuticals, Inc.

Net margin-33.0%FY2022

P/E snapshot-3.7xone ratio, not a verdict

Prism attention9.5%share across these five

Filing track recordRevenue, USD billions

+622.5%

FY2020–FY2022 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 168.8%

52-week position74% through range

$2.78$6.45

News mentions547

Community mentions74partial coverage

U.S.-scope patents497

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal42/100
Management stability90/100
Market position7/100
Capital-event signal36/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3ETST · OTC

Earth Science tech

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2014Doral, Florida$25.9M market cap

View full Companies Radar profile

38Cautious

Snapshot price$0.09as of page date

Monthly-close return+195.1%five-year window

FY2025 revenue$0.03BEarth Science Tech, Inc.

Net margin9.8%FY2025

P/E snapshot9.0xone ratio, not a verdict

Prism attention1.9%share across these five

Filing track recordRevenue, USD billions

+23404.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 291.5%

52-week position38% through range

$0.00$0.24

News mentions112

Community mentions0partial coverage

U.S.-scope patents2

Prism InsightsWhat sits behind the readiness signal
Observed risk 7/100higher means more observed risk

Earnings signal62/100
Management stability90/100
Market position7/100
Capital-event signal5/100
Innovation pulse20/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 1 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 2 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4NXTC · Nasdaq

NextCure

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2015New Haven, Connecticut$31.1M market cap

View full Companies Radar profile

38Cautious

Snapshot price$6.80as of page date

Monthly-close return-91.6%five-year window

FY2021 revenue$0.02BNextCure, Inc.

Net margin-310.1%FY2021

P/E snapshot-1.2xone ratio, not a verdict

Prism attention6.8%share across these five

Filing track recordRevenue, USD billions

+252.6%

FY2019–FY2021 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 87.8%

52-week position37% through range

$1.55$15.74

News mentions393

Community mentions11partial coverage

U.S.-scope patents77

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal47/100
Management stability90/100
Market position0/100
Capital-event signal40/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5SRPT · Nasdaq

Sarepta

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1980Cambridge, Massachusetts$2.25B market cap

View full Companies Radar profile

38Cautious

Snapshot price$21.33as of page date

Monthly-close return-76.9%five-year window

FY2025 revenue$1.86BSarepta Therapeutics, Inc.

Net margin-38.3%FY2025

P/E snapshot8.3xone ratio, not a verdict

Prism attention70.4%share across these five

Filing track recordRevenue, USD billions

+204.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 32.1%

52-week position62% through range

$14.68$25.32

News mentions4.1K

Community mentions0partial coverage

U.S.-scope patents1398

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal27/100
Management stability90/100
Market position0/100
Capital-event signal68/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Earth Science tech

+195.1%

Sarepta

-76.9%

Atea

-84.3%

NextCure

-91.6%

Cerecor

-99.7%

Latest revenue

USD billions, official filing scope shown on each company card.

Sarepta

$1.86B

Atea

$0.35B

Earth Science tech

$0.03B

NextCure

$0.02B

Cerecor

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Earth Science tech

9.8%

Atea

-33.0%

Sarepta

-38.3%

NextCure

-310.1%

Cerecor

-132642.4%

Prism news attention

Normalized share across these five names; attention is not quality.

Sarepta

70.4%

Cerecor

11.4%

Atea

9.5%

NextCure

6.8%

Earth Science tech

1.9%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Sarepta leads the conversation

It holds 70.4% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $1.86B.

Price path

Earth Science tech leads the available price paths

Its monthly-close return is +195.1% for the five-year window. At the other end, Cerecor is -99.7% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Earth Science tech has the widest latest margin

Its FY2025 net margin is 9.8%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Cerecor shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -7.2x while its five-year window price return is -99.7%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · SRPT

Sarepta

4,070available Prism news records

Prism top themes

Legal, arbitration & regulatory

166

Price action & investor response

131

Earnings & financial performance

Macro demand & rates

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+23.0%862 latest 12m vs 701 prior 12m

Machine-classified coverage tone

59.2% positive-5.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 270orphan drug pricing 123orphan drug incentives 114rare disease clinical trials 107rare disease treatment 92orphan drug exclusivity 55gene delivery systems 30stock performance 30

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-15–2026-06-12 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

AVIR

Atea

74 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 74 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

AVTX

Cerecor

through 2025-02-14

Leadership changes 2M&A 2Listing / IPO 1

2025-02-14
Listing / IPO
Cerecor Inc. entered an equity distribution agreement where it may offer and sell shares of its common stock having an aggregate gross sales price of up to $12 million.
2025-02-14
M&A
Cerecor is also merging with North Carolina company Zylera Pharma Corp. for $4 million, payable in Cerecor common stock.
2023-10-09
Leadership changes
Cerecor hired James Vornov, M.D. Ph.D., as svp, clinical development and regulatory affairs and John Kaiser as vp of commercialization and business development.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AVIR

Atea

through 2026-01-08

Company announcements 10Earnings releases 9Board updates 2M&A 1

2026-01-08
Company announcements
Atea will present the Company’s strategic priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San Francisco.
2025-03-26
Board updates
the Board appointed Arthur Kirsch in February 2025.
2024-02-28
Earnings releases
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ETST

Earth Science tech

through 2026-03-04

Earnings releases 10Regulatory 2Business contracts 1Company announcements 1Leadership changes 1

2026-03-04
Earnings releases
Earth Science Tech Inc. reported fiscal third-quarter 2026 revenue of $8.4 million, representing a 14.1% year-over-year increase, with gross margin expanding to 76.3% and adjusted EBITDA rising to $1.2 million.
2026-02-17
Company announcements
These actions build on the Company’s delivery of approximately $3.3 million in net income in the fiscal year ending March 31, 2025 and an anticipated $1.4 million in cost savings initiatives in the fiscal year ending March 31, 2026, which management believes would support approximately $4.7 million in net income on a go‑forward basis.
2026-01-23
Business contracts
Earth Science Tech Inc. (OTC: ETST), a strategic holding company, has engaged IBN , a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NXTC

NextCure

through 2026-03-31

Company announcements 3Earnings releases 3

2026-03-31
Earnings releases
NextCure N/A N/A -$55.84 million ($20.00) -0.54
2025-07-25
Company announcements
The surge in NextCure’s stock value came after the company presented new preclinical data for NC605, a potential treatment for brittle bone disease.
2025-07-25
Company announcements
Earlier in July, NextCure enacted a 1-for-12 reverse stock split, and its shares began trading on an adjusted basis.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SRPT

Sarepta

through 2026-03-05

Earnings releases 32Regulatory 11Company announcements 8Leadership changes 5Business contracts 1

2026-03-05
Leadership changes
Sarepta Therapeutics CEO Doug Ingram is stepping down from his post.
2026-02-26
Earnings releases
Overall, Sarepta achieved $1.86 billion in revenue for 2025.
2025-09-30
Regulatory
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2025 (the "Grant Date") that were approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in the third quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 121–128. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Cerecor leads the readiness ranking

Its Prism readiness score is 39/100, the highest in this five-company comparison.

Open Cerecor in Companies Radar

Scale and margin leadership sit with Sarepta and Earth Science tech

Sarepta has the largest displayed latest revenue at $1.86B; Earth Science tech has the widest displayed latest margin at 9.8%.

Open Sarepta in Companies Radar Open Earth Science tech in Companies Radar

Comparisons

Strongest versus weakest available price path

Earth Science tech is +195.1% for its five-year window; Cerecor is -99.7% for its five-year window.

Open Earth Science tech in Companies Radar Open Cerecor in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $1.86B for Sarepta to $0.00B for Cerecor. Entity and filing-period labels remain visible on the company cards.

Open Sarepta in Companies Radar Open Cerecor in Companies Radar

Anomalies

Sarepta has the widest attention-readiness rank gap

It ranks #1 by measured news attention (70.4%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Sarepta in Companies Radar

Atea shows a price-operating divergence to inspect

Its displayed filing-revenue change is +622.5% while its available monthly-close return is -84.3%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Atea in Companies Radar

Explanations

Attention measures coverage volume, not quality

Sarepta's 70.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Sarepta in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Cerecor's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 39/100 score.

Open Cerecor in Companies Radar

Stress-test the largest divergence before forming a view

Compare Atea's profile with Earth Science tech's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Atea in Companies Radar Open Earth Science tech in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.